A 24-week, international, multi centre, randomised, open label, parallel group, phase IV clinical trial investigating changes in bone formation markers in postmenopausal women with primary osteoporosis treated with either PTH (1-84) or strontium ranelate.

Trial Profile

A 24-week, international, multi centre, randomised, open label, parallel group, phase IV clinical trial investigating changes in bone formation markers in postmenopausal women with primary osteoporosis treated with either PTH (1-84) or strontium ranelate.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 May 2014

At a glance

  • Drugs Parathyroid hormone (Primary) ; Strontium ranelate
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Takeda Pharmaceuticals International GmbH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 May 2012 Additional company (Takeda Global Research and Development Center) added in association as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Actual end date (1 Sep 2009) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top